Condition: Cystic Fibrosis, 10011762 · Sponsor: Heidelberg University
OBJECTIVES Primary: To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age by means of lung clearance index (LCI). Secondary To evaluate safety and tolerability of treatment with anakinra as well as to investigate further effects of anakinra on lung function and quality of life (QOL) in subjects with CF.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University Children's Hospital Heidelberg, Cystic Fibrosis Centre | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| Universitätsmedizin Essen, Ruhrlandklinik | Essen, North Rhine-Westphalia, Germany | Recruiting |
| Charité - Universitätsmedizin Berlin | Berlin, State of Berlin, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03925194